Add BrightSurf on Google Email

Massachusetts General Hospital


New contrast agent could make MRIs safer

Researchers at MGH develop a new, possibly safer contrast agent for MRI exams using a manganese-based compound that provides comparable tumor contrast enhancement to state-of-the-art gadolinium-based agents. The new agent is designed to be more quickly and thoroughly cleared from the body, reducing concerns about long-term safety.

SourceMassachusetts General Hospital·JournalInvestigative Radiology·DateAug 15, 2019

Study identifies potential markers of lung cancer

Researchers at Massachusetts General Hospital have identified markers that can distinguish between major subtypes of lung cancer and accurately predict lung cancer stage. The study's findings could help physicians decide whether an individual patient with lung cancer benefits from standard treatment or needs more aggressive therapy.

SourceMassachusetts General Hospital·JournalScientific Reports·DateJul 16, 2019

Massachusetts General study identifies pathway linking socioeconomic status to cardiovascular risk

A new study by Massachusetts General Hospital identifies a biological pathway linking socioeconomic status to cardiovascular risk. The pathway involves brain stress centers, immune cell production, and arterial inflammation, which can be targeted by lifestyle approaches such as exercise, meditation, and statins.

SourceMassachusetts General Hospital·JournalJournal of the American College of Cardiology·DateJun 25, 2019

Tumor-selective angiotensin blockers may improve response to cancer immunotherapy

Researchers found that combining tumor-selective angiotensin blockers with immune checkpoint blockers significantly improves breast cancer treatment in mouse models. The combination treatment normalizes the tumor microenvironment, inducing changes in gene expression and activating immunosupportive pathways.

SourceMassachusetts General Hospital·JournalProceedings of the National Academy of Sciences·DateApr 29, 2019